Sana Biotechnology grants 90,000 options to director

Sana Biotechnology director Michelle Seitz received a grant of stock options for 90,000 shares of common stock.

Rhea-AI Filing Summary

Sana Biotechnology director Michelle Seitz received a grant of stock options for 90,000 shares of common stock. The options have an exercise price of $2.96 per share and expire on June 3, 2036. They vest and become fully exercisable on the earlier of June 4, 2027 or immediately prior to Sana’s 2027 annual stockholder meeting, as long as she continues to provide service to the company through that date. Following this award, she holds 90,000 stock options directly, reflecting a compensation-related acquisition rather than an open-market share purchase.

Insider Trade Summary

Grant/Award: 90,000 shares

Grant/Award 1 txn

Insider Seitz Michelle

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	90,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 90,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

Key Figures

Option grant size: 90,000 options Exercise price: $2.96 per share Expiration date: June 3, 2036 +3 more

6 metrics

Option grant size 90,000 options Stock Option (Right to Buy) grant to director

Exercise price $2.96 per share Conversion or exercise price of options

Expiration date June 3, 2036 Option expiration date

Vesting date trigger June 4, 2027 Earlier of this date or 2027 annual meeting

Underlying shares 90,000 shares Common stock underlying the options

Post-grant derivative holdings 90,000 options Total options held following transaction

Key Terms

Stock Option (Right to Buy), exercise price, vesting, expiration date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 2.9600 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"The option vests and becomes exercisable as to 100% of the underlying shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date: 2036-06-03T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying security financial

"underlying_security_title: Common Stock"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Sana Biotechnology director Michelle Seitz receive in this Form 4 filing for SANA?

Michelle Seitz received a grant of stock options for 90,000 shares of Sana common stock. The options are a compensation-related award, not an open-market purchase, and give her the right to buy shares at a fixed exercise price.

What is the exercise price of Michelle Seitz’s new Sana (SANA) stock options?

The stock options have an exercise price of $2.96 per share. This means Seitz can buy Sana common stock at $2.96 once the options vest and she chooses to exercise them before the options expire.

When do Michelle Seitz’s Sana Biotechnology (SANA) options vest?

The options vest 100% on the earlier of June 4, 2027 or immediately before Sana’s 2027 annual stockholder meeting. Vesting requires that Seitz continue to provide service to the company through the applicable vesting date.

When do the stock options granted to Michelle Seitz at Sana (SANA) expire?

The stock options expire on June 3, 2036. If Seitz does not exercise the options by that expiration date, they will lapse and she will no longer have the right to buy Sana common stock at the exercise price.

How many Sana Biotechnology (SANA) options does Michelle Seitz hold after this grant?

After this grant, Seitz holds 90,000 stock options directly. These options each relate to one share of Sana common stock and represent her reported derivative holdings following the compensation award described in the Form 4.

Is Michelle Seitz buying or selling Sana (SANA) shares in this Form 4?

She is not buying or selling shares on the open market; she is receiving a stock option grant. The Form 4 reports a compensation-related acquisition of 90,000 options, giving her the right to buy shares in the future at a fixed price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:39 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Seitz Michelle

(Last) (First) (Middle)

C/O SANA BIOTECHNOLOGY, INC.

188 EAST BLAINE STREET, SUITE 350

(Street)

SEATTLE WASHINGTON 98102

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sana Biotechnology, Inc. [ SANA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.96	06/04/2026		A		90,000		(1)	06/03/2036	Common Stock	90,000	$0.00	90,000	D

Explanation of Responses:

1. The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. ("Sana"), provided that the reporting person provides continuous service to Sana through such date.

Remarks:

Exhibit List: Ex. 24 - Power of Attorney

	/s/ Aaron M. Grossman, Attorney-in-Fact for Michelle Seitz	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)